Emcure FY26 Results: Revenue Crosses $1 Bn, PAT Up 33%
Emcure Pharmaceuticals reported a 16.6% rise in FY26 revenue to ₹92,035.40 million and a 33.1% increase in PAT to ₹9,412.69 million. The Board recommended a final dividend of ₹3.60 per share and re-appointed Dr. Mukund Gurjar and Mr. Satish Mehta as Whole-time Director and Managing Director, respectively.
*this image is generated using AI for illustrative purposes only.
Emcure Pharmaceuticals Limited has announced its audited financial results for the quarter and year ended March 31, 2026, reporting a strong performance with revenue crossing the $1 billion milestone. The company’s Board of Directors also approved the re-appointment of key directors and recommended a final dividend.
Financial Performance
For the full year FY26, the company reported a revenue from operations of ₹92,035.40 million, a 16.6% increase compared to ₹78,959.97 million in the previous year. Profit after tax (PAT) for the year stood at ₹9,412.69 million, marking a 33.1% year-on-year growth. In the fourth quarter (Q4 FY26), revenue reached ₹24,697.03 million, up 16.7% from ₹21,162.45 million in the corresponding period last year, while Q4 PAT increased by 23.6% to ₹2,437.36 million.
| Metric (₹ in million) | Year Ended Mar 31, 2026 | Year Ended Mar 31, 2025 | Growth |
|---|---|---|---|
| Revenue from Operations | 92,035.40 | 78,959.97 | 16.6% |
| Total Income | 92,162.04 | 79,632.58 | 15.7% |
| Profit for the Year | 9,412.69 | 7,074.67 | 33.1% |
| Earnings Per Share (Basic) | 48.77 | 36.43 | 33.9% |
Dividend Declaration
The Board of Directors has recommended a final dividend of ₹3.60 per equity share of ₹10 each (36%) for the financial year ended March 31, 2026. This dividend is subject to the approval of the shareholders at the ensuing Annual General Meeting.
Board Appointments
Based on the recommendations of the Nomination and Remuneration Committee, the Board approved the re-appointment of Dr. Mukund Gurjar (DIN: 00026843) as a Whole-time Director for a further period of one year commencing from August 28, 2026. Additionally, Mr. Satish Mehta (DIN: 00118691) has been re-appointed as the Managing Director for a period of five years commencing from April 01, 2027. Both appointments are subject to shareholder approval.
Dr. Mukund Gurjar has been associated with the company since July 23, 2001, and holds a Ph.D. from the Queen Elizabeth College, University of London. Mr. Satish Mehta, the Managing Director & CEO, is a Postgraduate in Chemistry from Pune University and holds a PGDM from IIM-Ahmedabad. The Board meeting regarding these appointments was held on May 05, 2026.
Operational Highlights
The company’s operational performance was driven by robust growth in international markets, which saw sales increase by 22.2% year-on-year to ₹51,770 million. Domestic business sales grew by 10.0% to ₹40,270 million. The Group’s EBITDA for the year stood at ₹1,789 crore with margins at 19.4%. The statutory auditors, M/s. B S R & Co. LLP, issued an unmodified opinion on the audited financial statements.
Historical Stock Returns for Emcure Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -2.16% | +2.26% | +7.59% | +26.50% | +59.61% | +26.08% |
Which specific international markets or therapeutic segments are expected to drive Emcure's next phase of growth beyond the $1 billion revenue milestone?
How might the 5-year re-appointment of Managing Director Satish Mehta influence Emcure's long-term strategic direction, including potential acquisitions or new market entries?
Given the 22.2% growth in international sales outpacing domestic growth of 10%, is Emcure considering expanding its subsidiary network beyond its current presence in 70 countries?
20
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
